Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Related to this article
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
2
Northwestern Medicine Study Finds Lung Transplant Dramatically Improves Survival for Patients With Terminal Lung Cancer
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
Dr Spencer on the Potential Role for In Vivo CAR T-Cell Therapy in Myeloma
5